- Home
- CRT vs TCRX Comparison
CRT vs TCRX Comparison
Compare CRT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | TCRX |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 49.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRT | TCRX |
|---|---|---|
| Price | $10.45 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 16.5K | ★ 454.6K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $7.07 | $0.72 |
| 52 Week High | $11.10 | $2.57 |
Technical Indicators
Market Signals| Indicator | CRT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 44.46 |
| Support Level | $10.15 | $0.72 |
| Resistance Level | $11.02 | $0.80 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 90.35 | 55.49 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.